Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806782 | PMC |
| http://dx.doi.org/10.1016/j.pbj.2017.07.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis.
Clin Ther
January 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:
Purpose: Mesalazine and thiopurines are important therapeutic agents for pediatric patients with ulcerative colitis (UC). Mesalazine, which may be administered in different forms depending on delivery mechanisms, can affect thiopurine metabolism, leading to increased 6-thioguanine nucleotides (6-TGN) levels. Therefore, when using these two drugs simultaneously, their interactions must be considered.
View Article and Find Full Text PDFTherapeutic Agents and Patient Characteristics Affecting Metabolism ofThiopurines in Patients with Inflammatory Bowel Disease.
Fukushima J Med Sci
December 2024
Department of Coloproctology and Gastroenterology, Aizu Medical Center Fukushima Medical University.
Objectives: In inflammatory bowel disease therapy, thiopurines have been essential. However, several reports have investigated factors affecting thiopurine metabolism to date. This study investigated factors affecting intracellular concentrations of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) in a real-world setting.
View Article and Find Full Text PDFLarge-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
J Clin Oncol
October 2024
Open Targets, Wellcome Genome Campus, Hinxton, United Kingdom.
Purpose: As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service.
Methods: Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes (, , , ) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants.
Analysis of Azathioprine Metabolites in Autoimmune Hepatitis Patient Blood-Method Development and Validation.
Int J Mol Sci
October 2024
Proteomics Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Egyetem tér 1, 4032 Debrecen, Hungary.
Article Synopsis
- Autoimmune hepatitis (AIH) is a chronic liver disease treated with steroids and the thiopurine drug azathioprine (AZA), which is metabolized into active forms like 6-thioguanine (6-TG) and 6-methyl-mercaptopurine (6-MMP).
- This study focused on creating a quick and effective ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) method to analyze levels of 6-TG and 6-MMP in blood samples from AIH patients.
- The new method was validated following EMA guidelines and proved to be accurate and precise for monitoring these important metabolites, facilitating better treatment management for patients.
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.
Intern Med J
November 2024
Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Article Synopsis
- Thiopurine co-therapy with anti-TNFα agents improves drug levels and reduces the chance of developing antibodies in patients with inflammatory bowel disease (IBD).* -
- A study analyzed the relationship between 6-thioguanine nucleotide (6-TGN) levels and anti-TNFα levels among IBD patients from 2015 to 2021, showing a significant link with infliximab but not adalimumab.* -
- The research identified optimal 6-TGN cut-off levels for effective therapeutic anti-TNFα levels, suggesting lower levels may suffice for treatment, particularly for infliximab.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!